Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented ...

CoDiagnostics, Inc. (CODX Quick Quote CODX - Free Report) shares ended the last trading session 9.7% higher at $8.62. The jump came on an impressive volume with a higher-than-average number of shares ...

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced ...

The molecular diagnostics firm revealed it has signed a Memorandum of Understanding with a Saudi Arabian partner to potentially create a joint venture aimed at developing and distributing its Co-Dx™ ...

CODX received its first issued patent for the Co-Dx PCR platform from the Australian Patent Office. CODX's patent covers the PCR Pro instrument and proprietary test cups for point-of-care use. CODX is ...

New York City, Dec. 19, 2019 (GLOBE NEWSWIRE) -- The CEO of Co-Diagnostics, Inc. (Nasdaq: CODX), a biotech with a patented platform for the development of molecular diagnostic tests that has been ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Co-Diagnostics (CODX) is a stock that can certainly grab the attention of many ...

Dividend history information is presently unavailable for this company. This could indicate that the company has never provided a dividend or that a dividend is pending. Nasdaq Data provided by Nasdaq ...